findmyKOL
Clinical trialNCT01363128CompletedPhase 2Interventional

Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

SponsorM.D. Anderson Cancer CenterEnrollment72Acute Lymphoblastic LeukemiaAdult Acute Lymphoblastic Leukemia in Complete RemissionBurkitt LeukemiaBurkitt LymphomaCD20 PositiveChildhood Acute Lymphoblastic Leukemia in Complete Remission+1 more conditions
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • M D Anderson Cancer Center

    Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
12 Jul 2011
Primary completion
8 Apr 2020
Completion
8 Apr 2020
Last update posted
3 May 2021
Registered enrollment
72
Registry id
NCT01363128

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.